The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.
Despite advances in defining the critical molecular determinants for leukemia stem cell (LSC) generation and maintenance, little is known about the roles of microRNAs in LSC biology. Here, we identify microRNAs that are differentially expressed in LSC-enriched cell fractions (c-kit(+)) in a mouse model of MLL leukemia. Members of the miR-17 family were notably more abundant in LSCs compared with their normal counterpart granulocyte-macrophage progenitors and myeloblast precursors. Expression of miR-17 family microRNAs was substantially reduced concomitant with leukemia cell differentiation and loss of self-renewal, whereas forced expression of a polycistron construct encoding miR-17-19b miRNAs significantly shortened the latency for MLL leukemia development. Leukemias expressing increased levels of the miR-17-19b construct displayed a higher frequency of LSCs, more stringent block of differentiation, and enhanced proliferation associated with reduced expression of p21, a cyclin-dependent kinase inhibitor previously implicated as a direct target of miR-17 microRNAs. Knockdown of p21 in MLL-transformed cells phenocopied the overexpression of the miR-17 polycistron, including a significant decrease in leukemia latency, validating p21 as a biologically relevant and direct in vivo target of the miR-17 polycistron in MLL leukemia. Expression of c-myc, a crucial upstream regulator of the miR-17 polycistron, correlated with miR-17-92 levels, enhanced self-renewal, and LSC potential. Thus, microRNAs quantitatively regulate LSC self-renewal in MLL-associated leukemia in part by modulating the expression of p21, a known regulator of normal stem cell function.
Wong
Piu
P
Department of Pathology and Microbiology, Stanford University School of Medicine, Stanford, California 94305-5324, USA.
Iwasaki
Masayuki
M
Somervaille
Tim C P
TC
Ficara
Francesca
F
Carico
Christine
C
Arnold
Christopher
C
Chen
Chang-Zheng
CZ
Cleary
Michael L
ML
D000818:Animals; D002453:Cell Cycle / Q000235:genetics; D002454:Cell Differentiation / Q000235:genetics; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics; D004195:Disease Models, Animal; D020869:Gene Expression Profiling; D015973:Gene Expression Regulation, Leukemic; D055785:Gene Knockdown Techniques; D005796:Genes; D016259:Genes, myc; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D023461:Myeloid Progenitor Cells / Q000473:pathology*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics; D014411:Neoplastic Stem Cells / Q000473:pathology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
C493957:Cdkn1a protein, mouse; D050759:Cyclin-Dependent Kinase Inhibitor p21; D035683:MicroRNAs; C543614:Mirn17 microRNA, mouse; D051788:Myeloid-Lymphoid Leukemia Protein
Mol Cell. 2008 May 23;30(4):460-71
18498749
Genes Dev. 2003 Sep 15;17(18):2298-307
12952893
Oncogene. 2003 Apr 17;22(15):2285-95
12700664
Mol Cell. 2007 Jul 6;27(1):91-105
17612493
Nature. 2005 Jun 9;435(7043):828-33
15944707
Mol Cancer. 2007 Sep 25;6:60
17894887
J Biol Chem. 2005 Jul 1;280(26):24315-21
15851483
Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40
18832181
Cell. 1993 Dec 3;75(5):855-62
8252622
Science. 2004 Jan 2;303(5654):83-6
14657504
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50
18308931
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9
16641092
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
16166262
Nature. 2005 Feb 17;433(7027):769-73
15685193
Mol Cell Biol. 2008 Apr;28(7):2167-74
18212054
Blood. 2007 May 15;109(10):4399-405
17284533
J Cell Mol Med. 2008 Sep-Oct;12(5A):1445-55
18554315
Cell. 2007 Sep 21;130(6):1005-18
17889646
Cancer Cell. 2006 Oct;10(4):257-68
17045204
Dev Biol. 1999 Dec 15;216(2):671-80
10642801
J Biol Chem. 2007 Jan 26;282(4):2135-43
17135249
Cell Stem Cell. 2009 Feb 6;4(2):129-40
19200802
Nature. 2005 Jun 9;435(7043):839-43
15944709
Blood. 2009 Jan 8;113(2):396-402
18941111
EMBO J. 2000 Sep 1;19(17):4655-64
10970858
Cancer Res. 2009 Feb 1;69(3):1109-16
19155294
Blood. 2009 Apr 2;113(14):3314-22
19188669
Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5078-83
16549775
Nat Cell Biol. 2007 Jul;9(7):775-87
17589498
Cell Death Differ. 2007 Apr;14(4):879-82
17218954
Genes Dev. 2009 Dec 15;23(24):2839-49
20008935
Cancer Res. 2001 Sep 1;61(17):6480-6
11522644
Genes Dev. 2003 Dec 15;17(24):3029-35
14701873
Leukemia. 2007 May;21(5):912-6
17330104
Genes Dev. 2009 Dec 15;23(24):2806-11
20008931
Cell. 2005 Jan 14;120(1):21-4
15652478
Genes Dev. 2007 Nov 1;21(21):2762-74
17942707
Curr Opin Hematol. 2008 Jul;15(4):352-8
18536574
J Exp Med. 2008 Mar 17;205(3):585-94
18299402
Nature. 2009 Jan 1;457(7225):51-6
19122635